FeesSafety
Pluang+

ARGX stock drops 10% after halting Phase 3 trial for Sjögren's disease due to futility

Market News
08 Oct 2026, 23:34 WIB
PRNewsWire
View Source
Bearish
ARGX stock drops 10% after halting Phase 3 trial for Sjögren's disease due to futility

argenx SE (ARGX) shares fell over 10% on October 8, 2026, after the company stopped its Phase 3 UNITY trial of subcutaneous Vyvgart for Sjögren's disease due to futility. An independent committee found the study unlikely to meet its primary endpoint, prompting discontinuation. Despite positive Phase 2 results for another drug, FB102, in celiac disease, the stock declined sharply. A securities law investigation has been announced for shareholders who suffered losses, with legal firm Levi & Korsinsky offering no-cost evaluations for potential claims.

Regarding argenx and its recent developments, here is Pluang's health sector market snapshot as of Oct 09, 2026 02:02 WIB: Among 128 priced health-sector US stocks tradable on Pluang, 40 rose and 88 fell. Notable movers include Summit Therapeutics Inc (SMMT) at USD 17.26 with a 1-day change of -3.84%, Crispr Therapeutics AG (CRSP) at USD 50.48 with a 1-day change of -3.57% and a Pluang order activity of 77% Sell / 23% Buy, and Cardinal Health Inc (CAH) at USD 240.26 with a 1-day change of +3.49% and 100% buy order activity. The most notable figure is the 88 stocks that fell today.

More News

DICK'S Sporting Goods favored over Coupang for 2027 due to profitability and valuation despite Coupang's growth.

DICK'S Sporting Goods favored over Coupang for 2027 due to profitability and valuation despite Coupang's growth.

Coupang leads South Korea's e-commerce with strong logistics but faces losses and regulatory challenges, including a major data breach. DICK'S Sporting Goods, expanding through Foot Locker acquisition, shows strong profitability, a solid dividend, an...

Market News
Neutral
19 minutes ago
AMD stock soars 140% in 2026, Nvidia lags but both poised for strong earnings growth by 2028.

AMD stock soars 140% in 2026, Nvidia lags but both poised for strong earnings growth by 2028.

In 2026, AMD's stock surged 140% due to strong growth in AI chips and server CPUs, with revenue and earnings expected to continue rising sharply through 2028. Nvidia, despite a 20% stock drop and leadership uncertainty, reported impressive revenue an...

Market News
Neutral
28 minutes ago
Berkshire Hathaway valued at $700 per share, driven by cash, stocks, and growing businesses under CEO Greg Abel.

Berkshire Hathaway valued at $700 per share, driven by cash, stocks, and growing businesses under CEO Greg Abel.

Berkshire Hathaway holds $352 billion in cash and Treasury bills and a $336 billion stock portfolio, covering over half its current share price. CEO Greg Abel's patient management and steady growth in operating businesses, including railroad and util...

Market News
Bullish
49 minutes ago
Gilead raises dividend for 11th year, backed by strong cash flow and expanding drug portfolio.

Gilead raises dividend for 11th year, backed by strong cash flow and expanding drug portfolio.

Gilead Sciences increased its dividend by 3.8% for the 11th consecutive year, supported by strong free cash flow of $10.6 billion over nine months and a conservative payout ratio below 30%. The company maintains a dominant position in HIV therapies w...

Company Fundamentals
Bullish
1 hour ago
Nvidia stock plunges 23% amid CEO resignation and investigations, trading at a record low P/E of 8.

Nvidia stock plunges 23% amid CEO resignation and investigations, trading at a record low P/E of 8.

Nvidia experienced its worst week since 2008, dropping 23% following CEO Jensen Huang's resignation and multiple investigations into chip exports to China. Despite a strong earnings report showing 103% revenue growth and raised guidance, the stock tr...

Market News
Bearish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App